With $97M, Latus pursues a different kind of Huntington’s gene therapy

<figure><div><img src="https://imgproxy.divecdn.com/G3XsVcjEEsY7RUeeyuhDwfcUgL9AKu_uzJpv0LpcZ60/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTQ4MTMyNzUyLmpwZw==.webp"/></div></figure><p>The therapy is par

Ben Fidler · 2026-05-04

With $97M, Latus pursues a different kind of Huntington’s gene therapy

The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.

Source: BioPharma Dive